Overview

Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome

Status:
NOT_YET_RECRUITING
Trial end date:
2030-06-30
Target enrollment:
Participant gender:
Summary
Subanesthetic dose of intravenous ketamine (KET) has been found to be highly effective in rapid treatment depression and associated suicidality but its exact mechanism of remains uncertain. This study will use a novel approach to elucidate KET's effects on the molecular/ gene expression pathways in living neurons obtained from the olfactory epithelium and correlate the changes to rapid improvement in depression via changes in the brain connectome. The study will identify the molecular targets and pathways involved in KET'S mechanism of rapid clinical action and pave the way for development of novel, more efficacious, and safer therapeutic agents.
Phase:
PHASE1
Details
Lead Sponsor:
Massachusetts General Hospital